Peripheral neurotoxicity induced by docetaxel

被引:101
作者
Hilkens, PHE
Verweij, J
Stoter, G
Vecht, CJ
vanPutten, WLJ
vandenBent, MJ
机构
[1] DR DANIEL DEN HOED CANC CTR, DEPT NEUROONCOL, 3008 AE ROTTERDAM, NETHERLANDS
[2] UNIV ROTTERDAM HOSP, ROTTERDAM, NETHERLANDS
[3] DR DANIEL DEN HOED CANC CTR, DEPT MED ONCOL, ROTTERDAM, NETHERLANDS
[4] DR DANIEL DEN HOED CANC CTR, DEPT BIOSTAT, ROTTERDAM, NETHERLANDS
关键词
D O I
10.1212/WNL.46.1.104
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Docetaxel, a new semisynthetic taxoid used as an antineoplastic agent, induced a predominantly sensory neuropathy in 20 of 41 patients. We assessed neurotoxicity in all patients participating in four phase II trials conducted in our institution. The neuropathy was evaluated by a clinical sum-score for symptoms and signs and by measurement of the Vibration Perception Threshold (VPT). The severity of neuropathy was graded according to the National Cancer Institute's Common Toxicity Criteria. Neuropathic symptoms were mild in most patients. However, at cumulative doses above 600 mg/m(2), 3 of 15 patients developed a moderate and 1 of 15 patients a severe neuropathy. There was a significant correlation between the cumulative dose of docetaxel and the post-treatment sum-score (p = 0.002). We found no correlation between post-treatment VPT and clinical sum-score or between post-treatment VPT and the cumulative dose of docetaxel. We conclude that docetaxel produces a mild and predominantly sensory neuropathy in a high proportion of treated patients. This neurotoxicity appeared to be dose dependent and may be severe and disabling at higher dose levels. Determination of the VPT is not a reliable method to monitor docetaxel-induced neuropathy.
引用
收藏
页码:104 / 108
页数:5
相关论文
共 25 条
[1]   DOCETAXEL (TAXOTERE) IN ADVANCED MALIGNANT-MELANOMA - A PHASE-II STUDY OF THE EORTC EARLY CLINICAL-TRIALS GROUP [J].
AAMDAL, S ;
WOLFF, I ;
KAPLAN, S ;
PARIDAENS, R ;
KERGER, J ;
SCHACHTER, J ;
WANDERS, J ;
FRANKLIN, HR ;
VERWEIJ, J .
EUROPEAN JOURNAL OF CANCER, 1994, 30A (08) :1061-1064
[2]  
AAPRO M, 1993, P AN M AM SOC CLIN, V12, P256
[3]  
BISSETT D, 1993, CANCER RES, V53, P523
[4]   CISPLATIN INDUCED NEUROPATHY - CENTRAL, PERIPHERAL AND AUTONOMIC NERVE INVOLVEMENT [J].
BOOGERD, W ;
HUININK, WWT ;
DALESIO, O ;
HOPPENBROUWERS, WJJF ;
VANDERSANDE, JJ .
JOURNAL OF NEURO-ONCOLOGY, 1990, 9 (03) :255-263
[5]   PHASE-I CLINICAL-TRIAL OF TAXOTERE ADMINISTERED AS EITHER A 2-HOUR OR 6-HOUR INTRAVENOUS-INFUSION [J].
BURRIS, H ;
IRVIN, R ;
KUHN, J ;
KALTER, S ;
SMITH, L ;
SHAFFER, D ;
FIELDS, S ;
WEISS, G ;
ECKARDT, J ;
RODRIGUEZ, G ;
RINALDI, D ;
WALL, J ;
COOK, G ;
SMITH, S ;
VREELAND, F ;
BAYSSAS, M ;
LEBAIL, N ;
VONHOFF, D .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (05) :950-958
[6]   VIBRATION PERCEPTION AND THERMOPERCEPTION AS QUANTITATIVE MEASUREMENTS IN THE MONITORING OF CISPLATIN INDUCED NEUROTOXICITY [J].
ELDERSON, A ;
VANDERHOOP, RG ;
HAANSTRA, W ;
NEIJT, JP ;
GISPEN, WH ;
JENNEKENS, FGI .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 1989, 93 (2-3) :167-174
[7]  
EXTRA JM, 1993, CANCER RES, V53, P1037
[8]   PHASE-II STUDY OF DOCETAXEL FOR RECURRENT OR METASTATIC NON-SMALL-CELL LUNG-CANCER [J].
FOSSELLA, FV ;
LEE, JS ;
MURPHY, WK ;
LIPPMAN, SM ;
CALAYAG, M ;
PANG, A ;
CHASEN, M ;
SHIN, DM ;
GLISSON, B ;
BENNER, S ;
HUBER, M ;
PEREZSOLER, R ;
HONG, WK ;
RABER, M .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (06) :1238-1244
[9]   PHASE-II TRIAL OF DOCETAXEL IN PATIENTS WITH STAGE-III AND STAGE-IV NON-SMALL-CELL LUNG-CANCER [J].
FRANCIS, PA ;
RIGAS, JR ;
KRIS, MG ;
PISTERS, KMW ;
ORAZEM, JP ;
WOOLLEY, KJ ;
HEELAN, RT .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (06) :1232-1237
[10]  
FUMOLEAU P, 1993, P AN M AM SOC CLIN, V12, P56